

2009 Physician Quality Reporting Initiative Patient-Level Measures

Each measure specified in the 2009 PQRI program includes a reporting frequency requirement, located in the instructions section, for each denominator-eligible patient seen during the claims-based reporting period (January 1 – December 31, 2009). Measure specification instructions limit the frequency of reporting necessary in certain circumstances (such as for patients with chronic illness for whom a particular process of care is provided periodically). The following list is a subset of the 2009 measures for which the reporting frequency is a minimum of once per reporting period per each individual eligible professional (NPI). In other words, these are considered patient-level or patient-process measures.

PQRI measures, including patient-level measure(s), may be reported for the same patient by multiple EPs practicing under the same Tax Identification Number (TIN). If a patient sees multiple providers during the reporting the period, that patient can be counted for each individual NPI reporting if the patient encounter(s) meet denominator inclusion.

The following is an example of two provider NPIs, billing under the same TIN who are intending to report PQRI Measure #5: Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD). Provider A sees a patient on February 2, 2009 and prescribes an ACE inhibitor and reports the appropriate QDCs for measure #5. Provider B sees the same patient at an encounter on July 16, 2009 and verifies that the patient has been prescribed and is currently taking an ACE inhibitor. Provider B must also report the appropriate QDCs for the patient at the July encounter to receive credit for reporting measure #5.

Measure Number	Measure Title
1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus
3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
6	Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
19	Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
41	Osteoporosis: Pharmacologic Therapy
47	Advance Care Plan
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy
53	Asthma: Pharmacologic Therapy
64	Asthma: Asthma Assessment
67	Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow
68	Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy
69	Multiple Myeloma: Treatment with Bisphosphonates
70	Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry
71	Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer

**2009 Physician Quality Reporting Initiative
Patient-Level Measures**

Measure Number	Measure Title
72	Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients
79	End Stage Renal Disease (ESRD): Influenza Immunization in Patients with ESRD
83	Hepatitis C: Testing for Chronic Hepatitis C - Confirmation of Hepatitis C Viremia
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment
85	Hepatitis C: HCV Genotype Testing Prior to Treatment
86	Hepatitis C: Antiviral Treatment Prescribed
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy
106	Major Depressive Disorder (MDD): Diagnostic Evaluation
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
110	Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old
111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 years and Older
112	Preventive Care and Screening: Screening Mammography
113	Preventive Care and Screening: Colorectal Cancer Screening
114	Preventive Care and Screening: Inquiry Regarding Tobacco Use
115	Preventive Care and Screening: Advising Smokers to Quit
117	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD)
119	Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients
121	Chronic Kidney Disease (CKD): Laboratory Testing (Calcium, Phosphorus, Intact Parathyroid Hormone (iPTH) and Lipid Profile)
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up
134	Screening for Clinical Depression and Follow-Up Plan
135	Chronic Kidney Disease (CKD): Influenza Immunization
136	Melanoma: Follow-Up Aspects of Care
137	Melanoma: Continuity of Care – Recall System
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care
152	Coronary Artery Disease (CAD): Lipid Profile in Patients with CAD
153	Chronic Kidney Disease (CKD): Referral for Arteriovenous (AV) Fistula
154	Falls: Risk Assessment
155	Falls: Plan of Care
156	Oncology: Radiation Dose Limits to Normal Tissues
163	Diabetes Mellitus: Foot Exam
173	Preventive Care and Screening: Unhealthy Alcohol Use – Screening
176	Rheumatoid Arthritis (RA): Tuberculosis Screening
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity
178	Rheumatoid Arthritis (RA): Functional Status Assessment
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis
180	Rheumatoid Arthritis (RA): Glucocorticoid Management
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV
186	Wound Care: Use of Compression System in Patients with Venous Ulcers